Listen: Paul Offit on Covid vaccines for kids, plus: how the Fed affects biotech, & another Alzheimer’s setback
Will biotech stocks ever recover? How well do Covid-19 vaccines work for kids? And can anything stop the amyloid hypothesis?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Longtime biotech investor Les Funtleyder joins us to explain why the recent interest rate hike is bad for biotech and just what it will take for the industry to get out of its slump. Then, vaccinologist and FDA adviser Paul Offit calls in to talk about the impending authorization of Covid-19 vaccines for young children and what it means for the future of the pandemic. We also explain the latest disappointing clinical trial in Alzheimer’s disease and some perplexing data on Pfizer’s Covid-19 antiviral.
